Brain tumor clinical trials open around the country all the time, and it can be hard for patients and care partners to keep track of new opportunities to consider participation in leading-edge clinical research. This report, generated by the National Brain Tumor Society, provides a summary of clinical trials that have started or begun recruitment since our last quarterly report. To learn more about each trial, and contact the party responsible for enrolling patients, just follow the link provided under the brief description of each listing.
- Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
- Brief Description: A phase III, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of AG-881 to placebo in participants will residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who…
